Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio
North America will account for 35% of the global interstitial cystitis (IC) drugs market
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report
Company Profiles
The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:
Amneal Pharmaceuticals Inc: The company offers interstitial cystitis and other related drugs such as Pyridium.
Astellas Pharma Inc: The company offers interstitial cystitis drugs such as Rosiptor.
Bayer AG: The company offers interstitial cystitis drugs such as Aleve and Aktion.
Eli Lilly and Co: The company offers interstitial cystitis and other related drugs such as Tadalafil.
Johnson and Johnson: The company offers interstitial cystitis drugs such as Elmiron.
Kyorin Pharmaceutical Co. Ltd.
Mission Pharmacal Co.
Perrigo Co. Plc
Pfizer Inc.
Purdue Pharma LP
Seikagaku Corp.
To gain access to more vendor profiles available with Technavio, buy the report!
Market Dynamics
The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.
Competitive Analysis
The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample
Market Segmentation
By type, the market is segmented into oral therapy and intravesical therapy. The oral therapy segment accounted for the largest share of the market.
By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America held the largest share of the market.
Related Reports:
Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.
Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Information sources
11.4 List of abbreviations
Exhibit 89: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Schools and colleges across the country rely on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) evaluations to assess and manage student-athlete concussions on the sidelines. However, this FDA-cleared tool is not recommended for...
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Martine Rothblatt PhD, JD, MBA, Chairperson and CEO of United Therapeutics, and inventor of SiriusXM Satellite Radio, will deliver the keynote address...
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...
Urban Wellness Group, a pioneering wellness provider, is proud to announce its official launch of new anti-aging and sleep enhancement treatments to southeast Portland.
Dr. Jason Zabell and Dr. Andy Swanson set themselves apart by pairing over 30...
Peninsula Canada, a global leading HR and health & safety firm, committed to making a positive impact in the community, is proud to announce a partnership with SickKids Foundation, a leading charity dedicated to supporting The Hospital for Sick...